|
Up a level |
Avila, E K; Chamberlain, M; Schiff, D; Reijneveld, J C; Armstrong, T S; Ruda, R; Wen, P Y; Weller, M; Koekkoek, J A F; Mittal, S; Arakawa, Y; Choucair, A; Gonzalez-Martinez, J; MacDonald, D R; Nishikawa, R; Shah, A; Vecht, C J; Warren, P; van den Bent, M J; DeAngelis, L M (2017). Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro-Oncology, 19(1):12-21.
Weller, M; Gorlia, T; Cairncross, J G; van den Bent, M J; Mason, W; Belanger, K; Brandes, A A; Bogdahn, U; Macdonald, D R; Forsyth, P; Rossetti, A O; Lacombe, D; Mirimanoff, R-O; Vecht, C J; Stupp, R (2011). Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology, 77(12):1156-1164.
Stupp, R; Hegi, M E; Mason, W P; van den Bent, M J; Taphoorn, M J B; Janzer, R C; Ludwin, S K; Allgeier, A; Fisher, B; Belanger, K; Hau, P; Brandes, A A; Gijtenbeek, J; Marosi, C; Vecht, C J; Mokhtari, K; Wesseling, P; Villa, S; Eisenhauer, E; Gorlia, T; Weller, M; Lacombe, D; Cairncross, J G; Mirimanoff, R O (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, 10(5):459-466.